We report the results of a phase I dose escalation trial of the multikinase inhibitor sorafenib in relapsed and refractory acute leukemia patients using an intermittent dosing regimen. Fifteen patients with advanced leukemia (12 with acute myeloid leukemia, 2 with acute lymphoblastic leukemia, 1 with biphenotypic) and a median age of 63 (range 37-85) years were enrolled and treated on a dose escalation trial. Toxicities Xgrade 3 were present in 55% of cycles and the maximum tolerated dose (MTD) was determined to be 400 mg b.i.d. Â 21days in a 28-day cycle. Plasma inhibitory assays of kinase targets extracellular signal-regulated kinase (ERK) and FLT3-internal tandem duplication (ITD) showed excellent target inhibition, with FLT3-ITD silencing occurring below the MTD. The N-oxide metabolite of sorafenib seemed to be a more potent inhibitor of FLT3-ITD than the parent compound. Despite marked ex vivo FLT-3 ITD inhibition, no patients met the criteria for complete or partial response in this monotherapy study. Out of 15 patients, 11 experienced stable disease as best response. Although sorafenib showed only modest clinical activity as a single agent in this heavily treated population, robust inhibition of FLT3 and ERK suggests that there may be a potential important role in combination therapies.
Introduction
Acute leukemia in adults remains difficult to cure with conventional cytotoxic chemotherapy, with B70% of adult patients diagnosed with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) dying of the disease. [1] [2] One recent strategy is based on targeting cellular signal transduction pathways found to be mutated or overactive in the malignant clone. Acute leukemia has several potential targetable pathways and one pathway of great interest is the Ras/Raf/MEK/Erk pathway because of its role in cellular division, differentiation and apoptosis. This pathway is constitutively activated in more than 50% of primary AML samples; 3 and constitutive activation is associated with an inferior clinical outcome. 4 This pathway can be activated by mutations in receptor tyrosine kinases such as FLT3, c-KIT and vascular endothelial factor. 5 Sorafenib is a multitargeted tyrosine kinase inhibitor, with activity against RAF kinase, vascular endothelial factor receptors, both wild-type and ITD (internal tandem duplication)-mutated FLT3, platelet-derived growth factor receptors, c-KIT and RET kinase. 6 Sorafenib was recently approved by the US Food and Drug Administration for the treatment of renal cell cancer 7 and hepatocellular carcinoma. 8 Preclinical studies of sorafenib in acute leukemia have shown downregulation of the mitogen-activated protein kinase pathway, sensitization to receptor-mediated apoptosis by downregulation of myeloid cell leukemia-1, [9] [10] and growth inhibition of AML cells with FLT3-ITD mutations. 11 Early published clinical studies of sorafenib in AML suggest that continuous dosing at a dose approved for solid tumors (400 mg twice daily) is not tolerated well in patients with AML/MDS. 12 Sorafenib has been found to occasionally induce hematological responses and complete remissions in select patients with FLT3-ITD AML. [13] [14] On the basis of these data and earlier work that suggested improved tolerance in intermittently dosed schedules, 15 we undertook a phase I dose escalation trial to determine the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of sorafenib given orally, twice daily (b.i.d.), for either 14 days or 21 days of a 28-day treatment cycle in patients with refractory acute leukemia. We also examined pharmacokinetics, pharmacodynamics and tumor response. Correlative studies included the assessment of target modulation by plasma inhibitory assay (PIA) of phosphorylated-extracellular signal-regulated kinase (ERK) and phosphorylated-FLT3-ITD using methods previously developed for FLT3 targeted therapies. [16] [17] In addition, we investigated the metabolism of sorafenib during intermittent dosing to assess residual active compounds found after discontinuation of sorafenib. This examination focused on one metabolite, sorafenib N-oxide, which was thought to have biological properties similar to those of the parent compound, 18 and has been reported to represent the most common metabolite representing B17% of circulating total drug. 19 Previous investigations of this metabolite have not studied its activity against mutated FLT3.
Patients and methods

Patient selection
Patients over the age of 18 years with pathological confirmation of relapsed or refractory AML, or ALL, were considered to be eligible. Standard end organ function and performance status criteria for phase I investigations were used, including bilirubin o2.0 mg/dl, AST/ALT o5 Â upper limit of normal and creatinine clearance 460 ml/min/1.73 m 2 . Patients were required to have a peripheral blast count o30 000/ml and not greater than a 50% increase in absolute blast count within the preceding week. Hydroxyurea was allowed up to 48 h after starting sorafenib. Protocol and consent form were approved by the Johns Hopkins School of Medicine Institutional Review Board. All patients gave informed consent according to the Declaration of Helsinki.
Treatment plan
Patients were initiated on twice daily oral tablet dosing of sorafenib for either 14 or 21 consecutive days of treatment in each 28-day cycle and were managed in the outpatient clinic. Table 1 lists the planned dosing levels. All patients were evaluated for DLT for the purpose of determining MTD.
Evaluation of response
Baseline evaluations, including an on-study bone marrow aspirate and biopsy, were conducted within 1 week before entry into the study. Bone marrow assessments were performed on or about cycle 1 day 8 (early treatment assessment), before initiation of cycle 2 and every two cycles thereafter. Clinical responses for AML and ALL were measured according to International Working Group definitions. 20 
Determination of DLT, MTD and stopping rules
All patients filled out medication and side effect/toxicity diaries that were reviewed weekly. Toxicities were graded according to the National Cancer Institute Common Toxicity Criteria, Version 3.0; http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. Dose escalation continued until a DLT occurred in two patients out of the three patients in a cohort. When one DLT was observed in the first three patients during the first treatment cycle at a given dose level, three additional patients (up to six patients in total) were treated at that level. When DLTs occurred in the first two or three patients treated at a given dose level, no further dose escalation occurred. The dose immediately below the dose level that produced two DLTs was considered the MTD. Patients without evidence of disease progression or DLT secondary to therapy were allowed to continue on that dose for a total of six cycles. No intrapatient dose escalation was permitted.
Pharmacokinetic studies
Serial blood samples were collected in lithium-heparin-containing tubes before and at 0.25, 0.5, 1, 2, 4, 6 and 8 h after the administration of the first dose of sorafenib. Additional blood samples were collected before administration (C min ) on day 2, 3, 8 and 15 of continuous dosing and before the start of cycle 2. Samples were processed within 30 min of collection by centrifugation for 10 min at 1500 Â g under refrigeration (B4 1C). The resultant plasma was stored at À70 1C until subsequent analysis for sorafenib and sorafenib N-oxide concentrations using a validated liquid chromatography/tandem mass spectrometry method. 21 Briefly, sorafenib and sorafenib Noxide were extracted from plasma using acetonitrile precipitation. Separation of sorafenib, sorafenib N-oxide and the internal standard, [ 2 H 3 15 N] sorafenib, was achieved on an X-Terra C 18 (150 mm Â 2.1 mm i.d., 3.5 mm; Waters, Milford, MA USA) analytical column using a mobile phase consisting of acetonitrile/10 mM ammonium acetate (65:35, v/v) containing 0.1% formic acid and isocratic flow at 0.2 ml/min for 6 min. Analytes were monitored by tandem mass spectrometry with electrospray positive ionization. Linear calibration curves were generated over the range of 0.007-7.26 mg/ml (0.02-15.6 mM) for sorafenib and of 0.01-2.5 mg/ml (0.2-5.2 mM) for sorafenib N-oxide. Plasma samples that were diluted 1:10 (v/v) with pooled plasma were accurately quantitated. The accuracy and within-and between-day precisions were within the acceptance criteria for bioanalytical assays. 22 Pharmacokinetic variables were calculated using standard noncompartmental methods using WinNonlin professional (version 5.2). 23 C max was the observed maximum concentration. T max was the time point at which C max was observed. C min was the observed minimum concentration or predose sampling. C min was determined to be valid if the interval between evening dose and the sample was within an allowed range of 12 ± 2 h and obtained before dosing. AUC) (0-8 h) was the observed area under the curve (AUC), calculated using a combination of linear and log trapezoidal rules. Pharmacokinetic parameters were summarized using descriptive statistics.
Correlative studies Inhibitors. Sorafenib was provided by Bayer Pharmaceuticals through the Investigational Drug Branch, Cancer Treatment Evaluation Program, National Cancer Institute. Sorafenib N-oxide was obtained from Toronto Research Chemicals. Sorafenib and sorafenib N-oxide were dissolved in dimethyl sulfoxide and stored at À80 1C as 10mM stock solutions. All samples in any given experiment contained identical concentrations of dimethyl sulfoxide.
Cell culture. All cell lines were cultured in RPMI/10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA) at 37 1C in 5% CO 2 . The TF/ITD cell line was derived by transfecting TF-1 cells (growth factor dependent) with an expression vector containing the FLT3 coding sequence containing an ITD mutation from an AML patient, as described. 16 The resultant TF/ITD line is growth factor independent and expresses constitutively phosphorylated FLT3 and ERK 1/2.
PIA assay. The PIA assay was performed as described previously using the TF/ITD cell line as the target cell line. 17 Phosphorylated ERK1/2(Cell Signaling, Danvers, MA, USA) was assessed in whole-cell lysates.
Results
Sorafenib phase I patient characteristics
Patient characteristics are listed in Table 2 and were typical of patients in early-phase leukemia trials with a median of 3 (range 1-6) previous therapies. 
Sorafenib-associated toxicities and MTD
Toxicities (any grade) that were potentially related to therapy were seen in 23 out of 31 cycles (74%; Table 3 ). Grade X3 toxicities were experienced in 17 (55%) cycles. Dose-limiting toxicities at 600 mg b.i.d. Â 14 days were observed in two out of three patients and included elevated transaminases (n ¼ 1); musculoskeletal back pain remained unimproved with standard measures. 1 On the basis of the DLT described at 600 mg b.i.d. Â 14 days, the dose of 400 mg b.i.d. Â 21 days was determined to be the MTD and further dose escalation did not occur.
Sorafenib and sorafenib N-oxide pharmacokinetics
All patients were evaluable for pharmacokinetic analysis (Supplementary Table 1 ). Sorafenib exhibited a variable plasma concentration-time profile with a slow absorption phase, followed by a long-terminal elimination phase, thus resulting in a relatively flat concentration-time profile as previously described. [24] [25] [26] [27] Sorafenib N-oxide exhibited a similar profile, with the maximum concentration occurring at the same time as that of the T max for sorafenib. 19 Moderate interindividual variability in pharmacokinetic parameters was noted, with a coefficient of variation for sorafenib AUC (0À8 h) and C max of up to 95 and 116%, respectively. Variability was higher for the sorafenib N-oxide metabolite, with the coefficient of variation for AUC (0À8 h) and C max of up to 129 and 124%, respectively. Sorafenib concentrations were detectable in 33% (one out of three) of patients after a 14-day break in treatment and in 80% (four out of five) of patients after a 7-day break. Sorafenib N-oxide was only detectable in 40% (two out of five) of patients after a 7-day break.
FLT3 and ERK inhibition
We prepared dose-response curves assessing the inhibitory potency of sorafenib on FLT-3 ITD autophosphorylation and ERK phosphorylation using TF-ITD cells in RPMI with 10% fetal bovine serum. Immunoblot analysis revealed an IC 50 of 1.2 nM for inhibition of phosphorylated FLT3 in media (data not shown). The IC 50 for inhibition of phosphorylated ERK was similar (0.91 nM, data not shown). Previous work with tyrosine kinase inhibitors has shown that most inhibitors in development are highly protein bound. [16] [17] 28 Therefore, we determined the IC 50 values of sorafenib for inhibition of phosphorylation of FLT3 and ERK using TF-ITD cells, substituting normal human plasma for culture medium. In plasma, the IC 50 of sorafenib for P-FLT3 inhibition shifts to B308 nM (Figure 1a ). ERK signaling in plasma was more resilient with an IC 50 rising to 841 nM ( Figure 1a ).
FLT3 inhibition at trough time points
Pharmacodynamic analysis of FLT3 and ERK targeting was performed on patients completing one cycle of therapy (n ¼ 9). Direct analysis of leukemic phosphoprotein status was difficult, as sufficient circulating leukemia cells were not available from most patients at each correlative time point because of low white blood count. We examined serial plasma specimens collected before treatment on days 1, 8, 15 and 29 in a PIA using an FLT-3 mutant cell line (TF-ITD) to assess target inhibition potential in an ex vivo setting. PIA data take into account protein binding, active metabolite levels and cytokine levels, which may influence target sensitivity to inhibition. Each of the patients studied (n ¼ 9) achieved complete inhibition of FLT3-ITD phosphorylation in the PIA on trough samples drawn while on therapy (Figure 2 ), suggesting that inhibition of FLT3-ITD occurs below 400 mg b.i.d.
Sorafenib inhibits FLT3 partially through a metabolite
To better understand the activity of sorafenib against FLT3 and ERK, we plotted the results of PIA assays with the pharmacokinetic values obtained at those time points (Figures 3a and b) . We then overlaid the standard curves for sorafenib suppression of FLT3-ITD in normal human plasma. Interestingly, we found that nearly all PIA assessments seemed to have a greater inhibitory activity than predicted by the standard curves with sorafenib alone. With the possibility of a drug metabolite contributing to the biological activity of sorafenib on FLT3, we assayed serial plasma samples for sorafenib's major metabolite, sorafenib N-oxide. Sorafenib N-oxide on an average was found at levels of B12% of sorafenib levels (median 8%, range 2-44%, s.d. 12%), with marked interpatient variability. We found the N-oxide metabolite to be more potent than sorafenib (B14.59-fold) at inhibiting autophosphorylation of FLT3-ITD and ERK in human plasma when assessed by western blotting in a cell-based assay using TF/ITD cells (Figure 1b) . To examine the additive effect of the presence of the N-oxide metabolite, we then replotted the PIA/PK data to account for the activity of the N-oxide metabolite of sorafenib by including the sum of the parent and metabolite PK values corrected for the increased potency (14.59-fold) of sorafenib N-oxide. This created an 'adjusted sorafenib concentration' value, which more closely approximated the sorafenib standard curve for P-FLT3 inhibition and P-ERK inhibition (Figures 3c and d) for samples in the inhibitory range.
FLT3 inhibitory activity is significant and extends up to 7 days after dosing
Plasma samples at trough obtained during the trial resulted in complete FLT3 silencing ( Figure 2 ) and the average drug concentrations (Supplementary Table 1 (14) 1 ( 
Clinical activity of sorafenib
The best response shown in 11 out of the 15 patients on this trial was stable disease. The longest duration of s.d. was 3 months, which was observed in two of the patients (13%). Although no patients met the criteria for complete or partial response, bone marrow blast counts decreased in 6 of the 15 (40%) patients after one cycle by an average of 18%. Supplementary Table 2 presents data before and after treatment for all patients on trial. Five of the nine patients treated on a 3-week schedule of drug showed a decrease in their bone marrow blasts, whereas only one of five evaluable patients treated on either of the 2-week schedules showed a decrease. Interestingly, this patient was the only one on the 2-week dosing schedule with an FLT3-ITD mutation. One of the two ALL patients cleared their peripheral blood blasts while on sorafenib and showed progressive improvement in bone marrow blasts, from 89% before treatment to 47% after cycle 1 and 45% after cycle 2. Interestingly, the patient had a mixed lineage leukemia-rearranged ALL with translocation. 4, 11 This translocation has been associated with overexpression of wild-type FLT3 and in vitro sensitivity to FLT3 inhibitors. [29] [30] Discussion Sorafenib can inhibit numerous potential pathways in acute leukemia, but despite such broad biological activity, we found relatively limited single-agent clinical activity. The clinical activity in our study population was limited to the observation of reduced bone marrow blasts in 56% (five out of nine) of patients treated at 400 mg b.i.d. Â 21 days and in one patient with FLT3-ITD AML treated in the 14-day schedule. Dose escalation beyond 400 mg b.i.d. was limited because of grade 3 and 4 toxicities. Similar clinical activity and toxicity has been reported with single-agent sorafenib administered continuously, in which 11 out of 20 patients were found to have a 450% reduction in peripheral blood blasts and 9 of 11 patients with FLT3-ITD AML had measured responses, including one morphological bone marrow CR. 31 One potential explanation for the lack of improved tolerance to our intermittent dosing was the demonstration of prolonged biological activity after therapy completion.
Interestingly, in AML, one target of great importance is FLT3-ITD, and in our study, sorafenib showed suppression of FLT3-ITD at dosing below the MTD. Previous studies targeting FLT3-ITD with lestaurtinib documented the association of sustained complete or near complete inhibition of FLT3-ITD with clinical response; 32 but unlike the use of lestaurtinib, sorafenib uniformly suppressed FLT3-ITD in all samples assessed by PIA. This finding was somewhat surprising on the basis of sorafenib pharmacokinetics and preclinical studies of sorafenib alone. However, our correlative studies suggest the sorafenib N-oxide metabolite contributes significantly to in vivo FLT3-ITD inhibition. This inhibitory activity persisted up to 7 days after the completion of drug dosing in several patients. This observation is clinically important, with preclinical modeling of FLT3 inhibitors in combination with cytarabine and daunorubicin showing antagonism when the FLT3 inhibitor was used before conventional therapy. 33 There may be a need for a washout period before the use of cell-cycle dependent salvage or even consolidative treatments with the concomitant use of sorafenib.
The targeting of signal transduction pathways has therapeutically yet to be broadly successful. Even attempts to target a pathway thought to be as tissue specific as mutated FLT3 in AML has proven to be more complicated than many Figure 2 Plasma inhibitory assay (PIA) results for patients receiving sorafenib. Plasma was isolated from whole-blood samples obtained from patients receiving increasing doses of sorafenib on the clinical trial. Samples were obtained immediately before dosing on days 1, 8, 15 and 29 of each cycle. Dose levels 1, 2 and 3 correspond to total daily doses of 800, 800 and 1200 mg, respectively (see Table 1 ). Shown are the results from representative patients on successively higher dose levels using the PIA assay on TF-ITD cells for phosphorylated FLT3 (left) and ERK (right). For dose levels 2 and 3, extra time points on day 1 show complete silencing of FLT3 activity within 2 h of the first dose, with maintenance of this inhibition throughout the treatment cycle. Vertical lines have been inserted to indicate a repositioned gel lane. first appreciated. For example, the individual type of mutation is certainly critical, as preclinical studies suggest that patients with a D835Y mutation in FLT3 are unlikely to be sensitive to some FLT3 inhibitors such as sorafenib. 11 Moreover, there is evidence that allelic burden of FLT3-ITD is important for ex vivo sensitivity of primary leukemia blasts to FLT3 inhibition, and perhaps those with a high allelic ratio may be a subset that benefits the most from FLT3 targeted therapy. [34] [35] In addition, the clinical activity of targeted agents can be influenced by protein binding and drug-drug interactions. [32] [33] Our study, similar to others, has shown that the activity of metabolites of the primary agent may in fact have a major role in an agent's biological activity. 16 Finally, the disease state must also be factored into the equation, as targeting mutated pathways at the time of minimal residual disease, such as post induction, or after a stem cell transplant, might have the best opportunity to suppress the leukemic clone long term. 13 Taken together, future clinical studies of targeted agents must include biological correlatives if we hope to fulfill the hope that the new agents can affect clinical outcomes in a more discriminate manner.
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